Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03599622
Other study ID # IM011-023
Secondary ID 2017-001976-48
Status Terminated
Phase Phase 2
First received
Last updated
Start date July 16, 2018
Est. completion date October 23, 2023

Study information

Verified date January 2024
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.


Recruitment information / eligibility

Status Terminated
Enrollment 241
Est. completion date October 23, 2023
Est. primary completion date December 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Documented diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening, including ileal, colonic, or ileo-colonic disease distribution - Must have had an inadequate response, loss of response, or intolerance to 1 or more of the standard treatments - Must have active moderate to severe CD - Men and women must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Severe or fulminant colitis that is likely to require surgery or hospitalization - Presence of a diagnosis of alternative forms of colitis (infectious, inflammatory including ulcerative colitis, malignant, toxic, indeterminate, etc.) other than Crohn's Disease - Previous exposure to BMS-986165 in any study - Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, psychiatric, or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the participant Other protocol-defined inclusion/exclusion criteria apply

Study Design


Intervention

Drug:
BMS-986165
Specified dose on specified days
Other:
Placebo
Specified dose on specified days

Locations

Country Name City State
Australia Local Institution - 0265 Adelaide South Australia
Australia Local Institution - 0042 Ballarat Victoria
Australia Local Institution - 0041 Clayton Victoria
Australia Local Institution - 0040 Melbourne Victoria
Australia The Alfred Hospital Melbourne Victoria
Australia Local Institution - 0275 Murdoch Western Australia
Australia Local Institution - 0268 South Brisbane Queensland
Australia Local Institution - 0289 Woodville South Australia
Australia Princess Alexandra Hospital Woolloongabba Queensland
Belgium Local Institution - 0316 Antwerpen
Belgium Local Institution - 0305 Edegem
Belgium Local Institution - 0322 Gent
Belgium Local Institution - 0314 Yvoir
Brazil Hospital das Clinicas da Faculdade de Medicina de Botucatu Botucato SAO Paulo
Brazil Local Institution - 0069 Juiz de Fora Minas Gerais
Brazil Local Institution - 0086 Porto Alegre Rio Grande Do Sul
Brazil Local Institution - 0017 Rio de Janeiro
Brazil Local Institution - 0256 Salvador Bahia
Brazil Local Institution - 0262 Salvador Bahia
Brazil Local Institution - 0059 Santo Andre Sao Paulo
Brazil Local Institution - 0045 Sao Bernardo do Campo SAO Paulo
Brazil Local Institution - 0085 Sao Jose do Rio Preto SAO Paulo
Canada University of Calgary Calgary Alberta
Canada Local Institution - 0324 Edmonton Alberta
Canada South Edmonton Gastroenterology Research Clinic Edmonton Alberta
Canada Local Institution - 0312 London Ontario
Canada McGill University Health Centre Montreal Quebec
Canada Sunnybrook Health Sciences Centre Toronto Ontario
Canada Local Institution - 0159 Vancouver British Columbia
Canada Local Institution - 0283 Vaughan Ontario
China Local Institution - 0250 Changchun Shi Jilin
China Local Institution - 0221 Changsha Hunan
China Local Institution - 0225 Guangzhou Guangdong
China Local Institution - 0228 Guangzhou Guangdong
China Local Institution Nanjing Jiangsu
China Local Institution - 0306 Nanjing Jiangsu
China Local Institution - 0219 Shanghai Shanghai
China Local Institution - 0234 Shanghai Shanghai
China Local Institution Shenyang Liaoning
China Local Institution - 0280 XIamen Fujian
Czechia Local Institution - 0337 Brno
Czechia Local Institution - 0360 Brno
Czechia Local Institution - 0057 Hradec Kralove
Czechia Local Institution - 0071 Ostrava
Czechia Local Institution - 0352 Ostrava
Czechia Local Institution - 0350 Pardubice
Czechia Klinicke centrum ISCARE IVF a.s. Praha 9
Denmark Local Institution - 0192 Aalborg
Denmark Local Institution - 0202 Copenhagen NV
Denmark Local Institution - 0320 Odense
France Local Institution - 0110 Clichy Cedex
France Local Institution - 0168 Colombes
France Local Institution - 0343 Montpellier cedex 5
France Local Institution - 0084 Saint-Etienne
France Local Institution - 0167 Toulouse
France Local Institution - 0127 Toulouse Cedex 9
Germany Charite Universitatsmedizin Berlin Berlin
Germany Local Institution - 0099 Berlin
Germany Stadtisches Klinikum Brandenburg Brandenburg An Der Havel
Germany Local Institution - 0212 Frankfurt
Germany Local Institution Halle
Germany Studiengesellschaft BSF UG Halle
Germany Medizinische Hochschule Hannover Hannover
Germany Local Institution - 0089 Jena
Germany Local Institution - 0190 Kiel
Germany Local Institution - 0321 Mannheim
Germany Local Institution - 0140 Munster
Germany Local Institution - 0257 Regensburg
Germany Universitatsklinikum Tubingen Tubingen
Germany Local Institution - 0102 Ulm
Hungary Local Institution - 0104 Bekescsaba
Hungary Local Institution - 0100 Budapest
Hungary Local Institution - 0211 Budapest
Hungary Local Institution - 0242 Budapest
Hungary Local Institution - 0263 Budapest
Hungary Local Institution - 0292 Budapest
Hungary Local Institution - 0054 Debrecen
Hungary Local Institution - 0083 Gyongyos
Hungary Local Institution - 0210 Mohacs
Hungary Local Institution - 0243 Szeged
Hungary Local Institution - 0164 Vac
Ireland Local Institution - 0335 Ballinasloe Galway
Ireland Local Institution - 0336 Drogheda Louth
Ireland Local Institution - 0330 Dublin
Ireland Local Institution - 0332 Galway
Ireland Local Institution - 0348 Tallaght Dublin
Israel Local Institution Beer Sheva
Israel Local Institution - 0186 Nahariya
Israel Local Institution - 0184 Petah Tikva
Israel Local Institution - 0198 Rehovot
Italy Local Institution - 0290 Bologna
Italy Local Institution - 0298 Castellana Grotte
Italy Local Institution - 0171 Catanzaro
Italy Clinica Medica Azienda Ospedaliera Universitaria Messina
Italy ASST Santi Paolo e Carlo - Ospedale San Paolo Polo Universitario Milano
Italy Local Institution - 0304 Milano
Italy Polo Universitario - LAzienda Ospedaliera Luigi Sacco Milano
Italy Local Institution - 0297 Monserrato
Italy Local Institution - 0310 Negrar
Italy Local Institution - 0128 Padova
Italy Local Institution - 0170 Pavia
Italy Local Institution - 0161 Roma
Italy Local Institution - 0119 Rozzano
Italy Ospedale Mauriziano Umberto I di Torino Torino
Japan Local Institution - 0213 Bunkyo-ku Tokyo
Japan Fukuoka University Chikushi Hospital Chikushino Fukuoka
Japan Local Institution Chikushino-shi Fukuoka
Japan Local Institution - 0326 Fukui-shi Fukui
Japan Local Institution - 0189 Hamamatsu Shizuoka
Japan Local Institution - 0199 Hirosaki Aomori
Japan Local Institution - 0188 Hiroshima
Japan Kurume University Hospital Kurume Fukuoka
Japan Local Institution - 0206 Kyoto
Japan Local Institution - 0195 Minato-ku Tokyo
Japan University of Miyazaki Hospital Miyazaki
Japan Local Institution - 0183 Nishinomiya Hyogo
Japan National Hospital Organization Nagasaki Medical Center Omura-shi Nagasaki
Japan Local Institution - 0185 Otsu Shiga
Japan Local Institution - 0196 Saga
Japan Local Institution - 0207 Sagamihara-shi Kanagawa
Japan Local Institution - 0205 Sakura-shi Chiba
Japan Local Institution - 0203 Sapporo
Japan Sapporo Higashi Tokushukai Hospital Sapporo Hokkaido
Japan Sapporo Medical University Hospital Sapporo Hokkaido
Japan Local Institution - 0200 Sendai Miyagi
Japan Local Institution - 0179 Suita-shi Osaka
Japan Local Institution - 0328 Toon Ehime
Japan Local Institution - 0182 Toyoake Aichi
Japan Urasoe General Hospital Urasoe-Shi Okinawa
Korea, Republic of Local Institution Ansan-si
Korea, Republic of Local Institution Busan
Korea, Republic of Local Institution - 0061 Daegu
Korea, Republic of Local Institution - 0064 Daegu
Korea, Republic of Local Institution Incheon
Korea, Republic of Local Institution - 0046 Seongnam-si Gyeonggi-do
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution - 0012 Wonju-si
Korea, Republic of Local Institution Yangsan-si
Mexico Local Institution - 0009 Cuernavaca Morelos
Mexico Local Institution - 0106 Guadalajara Jalisco
Mexico Local Institution - 0007 Mexico Distrito Federal
Mexico Local Institution - 0109 Monterrey Nuevo LEON
Mexico Local Institution - 0029 Queretaro
Netherlands Local Institution - 0303 Amsterdam
Poland Local Institution - 0177 Bydgoszcz
Poland Local Institution - 0245 Bydgoszcz
Poland Local Institution - 0065 Krakow
Poland Local Institution - 0098 Lodz
Poland Local Institution - 0284 Lodz
Poland Local Institution - 0291 Lublin
Poland Local Institution - 0278 Nowy Targ
Poland ETYKA Osrodek Badan Klinicznych Olsztyn
Poland Endoskopia Sopot
Poland Local Institution - 0063 Tychy
Poland Local Institution - 0271 Warszawa
Poland Local Institution - 0279 Warszawa
Poland Local Institution - 0288 Warszawa
Poland Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED Jadwiga Miecz Warszawa
Poland Centrum Medyczne Oporow Wroclaw
Poland PlanetMed sp.z o.o. Wroclaw
Portugal Local Institution - 0174 Guimaraes
Portugal Local Institution - 0216 Santa Maria da Feira
Romania Spitalul Universitar de Urgenta Bucuresti Bucharest
Romania Centrul Medical Sana Bucuresti
Romania Hyperclinica MedLife Grivita Bucuresti
Romania Local Institution - 0044 Bucuresti
Romania Centrul Medical Tuculanu Timisoara
Romania Local Institution - 0005 Timisoara
Russian Federation Bioterm Barnaul
Russian Federation Hospital Irkutsk Scientific Center Irkutsk
Russian Federation Republican Clinical Hospital Ministry of Health Republic of Tatarstan Kazan
Russian Federation City Clinical Hospital Number 24 Moscow
Russian Federation Medical Center Healthy Family Novosibirsk
Russian Federation Medical Center SibNovoMed Novosibirsk
Russian Federation Novosibirsk Gastrocenter Novosibirsk
Russian Federation Novosibirsk State Regional Clinical Hospital Novosibirsk
Russian Federation Clinic Ultrasound 4D Pyatigorsk
Russian Federation Saint Petersburg State Budgetary Institution of Health City Hospital of the Holy Martyr Elizabeth Saint-Petersburg
Russian Federation Saratov Regional Clinical Hospital Saratov
Russian Federation Tomsk Regional Clinical Hospital Tomsk
Russian Federation Multidisciplinary Consultative and Diagnostic Center Tyumen
Russian Federation Novgorod Regional Clinical Hospital Velikij Novgorod
Spain Local Institution - 0329 Alicante
Spain Local Institution - 0274 Barcelona
Spain Local Institution - 0154 Fuenlabrada
Spain Local Institution - 0080 Girona
Spain Local Institution - 0021 Las Palmas de Gran Canaria
Spain Local Institution LHospitalet de Llobregat
Spain Corporacio Sanitaria Parc Tauli Sabadell
Spain Local Institution - 0113 Santander
Spain Local Institution - 0309 Santiago De Compostelle
Spain Hospital Universitario Virgen Macarena Sevilla
Spain Local Institution - 0107 Sevilla
Spain Hospital Clinico Universitario de Valencia Valencia
Switzerland Local Institution - 0180 Bern
Taiwan Local Institution Kaohsiung
Taiwan Local Institution Taichung
Taiwan Local Institution - 0267 Taipei City
Taiwan Local Institution - 0152 Taoyuan
United Kingdom Local Institution - 0341 Birmingham
United Kingdom Blackpool Teaching Hospitals NHS Foundation Trust Blackpool
United Kingdom Local Institution - 0235 Cambridge
United Kingdom MAC Clinical Research - Cannock Cannock
United Kingdom Warrington and Halton Hospitals NHS Foundation Trust Cheshire
United Kingdom Local Institution - 0157 Glasgow
United Kingdom MAC Clinical Research - Manchester Manchester
United Kingdom Local Institution - 0208 Swansea
United States Texas Clinical Research Institute Arlington Texas
United States Kaiser Permanente Colorado Institute for Health Research Aurora Colorado
United States Clinical Trials of South Carolina Charleston South Carolina
United States Clinical Research Institute of Michigan Chesterfield Michigan
United States Local Institution - 0003 Chesterfield Michigan
United States The University of Chicago Medicine Chicago Illinois
United States Local Institution - 0255 Clearwater Florida
United States Digestive Health Associates of Texas - Richardson Garland Texas
United States Illinois Gastroenterology Group Glenview Illinois
United States The Medical Research Center of Connecticut Hamden Connecticut
United States Penn State Health Milton S. Hershey Medical Center Hershey Pennsylvania
United States Local Institution - 0301 Indianapolis Indiana
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States University of Mississippi Medical Center Jackson Mississippi
United States Local Institution - 0261 Jacksonville Florida
United States University of Florida Health - Jacksonville Jacksonville Florida
United States New York Langone Long Island Clinical Research Associates Lake Success New York
United States Florida Center for Gastroenterology Largo Florida
United States Local Institution - 0011 Las Vegas Nevada
United States GastroIntestinal Biosciences Los Angeles California
United States Local Institution Lynchburg Virginia
United States University of Miami Miller School of Medicine Miami Florida
United States Local Institution - 0356 Milwaukee Wisconsin
United States Atrium Health Monroe North Carolina
United States Vanderbilt Inflammatory Bowel Disease Clinic Nashville Tennessee
United States Advanced Research Institute - New Port Richey New Port Richey Florida
United States New York-Presbyterian Columbia University Medical Center New York New York
United States Digestive Health Center - Ocean Springs Ocean Springs Mississippi
United States Local Institution - 0349 Oklahoma City Oklahoma
United States Florida Hospital Orlando Orlando Florida
United States Omega Research Consultants - Maitland Orlando Florida
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Hunter Holmes McGuire Veterans Administration Medical Center Richmond Virginia
United States Local Institution - 0359 Saint Louis Missouri
United States Gastroenterology Research of San Antonio San Antonio Texas
United States Local Institution - 0307 San Antonio Texas
United States Local Institution - 0122 Sayre Pennsylvania
United States Local Institution - 0266 Seattle Washington
United States Local Institution - 0327 Seattle Washington
United States University of Washington Seattle Washington
United States Local Institution - 0282 Shreveport Louisiana
United States Spring Gastroenterology Associates - Houston Spring Texas
United States Local Institution - 0277 Suwanee Georgia
United States Local Institution - 0358 Suwanee Georgia
United States Local Institution - 0166 Tampa Florida
United States Local Institution - 0302 Tyler Texas
United States Local Institution - 0331 Vancouver Washington
United States Local Institution - 0047 Wyoming Michigan
United States US Digestive Disease Associates - Wyomissing Wyomissing Pennsylvania
United States Huron Gastroenterology Associates Ypsilanti Michigan
United States Florida Medical Clinic - Clinical Research Division Zephyrhills Florida

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Brazil,  Canada,  China,  Czechia,  Denmark,  France,  Germany,  Hungary,  Ireland,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  Netherlands,  Poland,  Portugal,  Romania,  Russian Federation,  Spain,  Switzerland,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants achieving clinical remission at Week 12 Clinical remission defined by Crohn's Disease Activity Index (CDAI) Week 12
Primary Proportion of participants achieving endoscopic response at Week 12 Endoscopic response defined by Simple Endoscopic Score for Crohn's Disease (SES-CD) Week 12
Secondary Proportion of participants who achieve a clinical response at Week 12 Week 12
Secondary Proportion of participants who achieve PRO2 [Participant reported outcome based on the stool frequency and abdominal pain components of the Crohn's Disease Activity Index (CDAI)] remission at Week 12 Week 12
Secondary Change from baseline in SES-CD (Simple Endoscopic Score for Crohn's Disease) at Week 12 Week 12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01958827 - A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease Phase 3